NCT06485089Completed
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers in Women With Obesity and Other Risk Factors for Breast Cancer
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 25 (actual)
- First submitted
- 20 Jun 2024
- Start date
- 14 Sept 2024
- Primary completion date
- 25 Mar 2026
- Lead sponsor
- University of Kansas Medical Center
- Diseases
- Obesity
- NCT number
- NCT06485089
What you commit to
- Study type: Observational
- Participants enrolled: 25
- From 14 Sept 2024 to the primary completion date, 25 Mar 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- • Subglandular breast implants (women with subpectoral implants are eligible if C cup or greater; breast can easily be pulled off the chest wall; and with approval of PI)
- Clinical contra-indication to incretin mimetics
- Insurance/third party has denied coverage and participant does not wish to do self-pay.
- Child-bearing potential and not on contraceptives
- Prior invasive breast cancer
- Currently taking any of the following medications: insulin, tamoxifen, raloxifene, letrozole, arimidex, exemestane, incretin mimetics.
Who the study is looking for
- • BMI 30-45 kg/m2
- Female
- Insurance approved or likely approved for tirzepatide clinical use \*
- Additional risk factors for breast cancer other than obesity (any one or more) First or second degree with breast cancer Known high density on mammogram (heterogenous or extremely dense) Prior biopsy showing atypical hyperplasia or LCIS Prior treated DCIS Known carrier breast cancer predisposition gene mutation or known mutation in family member .
- 2- fold or higher estimated 10 year or lifetime risk compared to population by standard risk model (BCRAT, BCSC, IBIS
Age in the registry: 40 years to 64 years · Sex: Female · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Kansas Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Unknown status |
| University of Kansas Medical Center Breast Cancer Prevention Center Coordinator of this site? Confirm its status | Westwood | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.